Urology Doctors in Idaho Falls, ID Accepting Medicare

6 Urology doctors found. Showing 1 - 6

Dr. Timothy Osborn Taylor, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2330 Coronado St, Idaho Falls, ID 83404 Phone: 208-552-1234    Fax: 208-522-9580

Richard Alan Blatter, D.O. Urology Medicare: Accepting Medicare Assignments Practice Location: 2001 S Woodruff Ave Ste 4, Idaho Falls, ID 83404 Phone: 208-524-4511    Fax: 208-524-4540

Jared K. Manwaring, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 2375 Coronado St, Idaho Falls, ID 83404 Phone: 208-552-1234    Fax: 208-529-1948

Dr. Peter M Cannon, M.D. Urology Medicare: Medicare Enrolled Practice Location: 2001 S Woodruff Ave, Suite 4, Idaho Falls, ID 83404 Phone: 208-524-4511    Fax: 208-524-4540

Dr. Duncan Dwaynne Harris, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 3200 Channing Way Ste A205, Idaho Falls, ID 83404 Phone: 208-535-4580

Dr. Roger H Tall, MD Urology Medicare: Medicare Enrolled Practice Location: 2001 S Woodruff, Suite 8, Idaho Falls, ID 83404 Phone: 208-529-0633    Fax: 208-529-1948

News Archive

Study finds TBS as independent contributor to fracture risk assessment

One of the most recent and extensively studied determinants of fracture risk is trabecular bone score (TBS). TBS, which is assessed by lumbar spine dual-energy X-ray absorptiometry (DXA) imaging, provides information about the micro-architectural deterioration of bone tissue. Previous studies have shown that TBS predicts fracture in postmenopausal women and older men. TBS is currently used in conjunction with BMD values to enhance the predictive ability of the widely used Fracture Risk Assessment tool (FRAX), a calculator used to assess an individual's 10-year risk of major osteoporotic fracture.

Study: Synthetic triglyceride oil may provide hope for people with Huntington's disease

An early study suggests that a synthetic triglyceride oil called triheptanoin may provide hope for people with Huntington's disease. The study is published in the January 7, 2015, online issue of Neurology, the medical journal of the American Academy of Neurology.

Shire, Janssen enter development and marketing agreement for Resolor

Shire plc, the global specialty biopharmaceutical company, announced today that it has acquired the rights to develop and market Resolor (prucalopride) in the United States (US) in an agreement with Janssen Pharmaceutica N.V.

Researchers investigate individual responses and mechanisms for the increase in soft drink consumption

In spite of health warnings about high consumption of carbonated soft drinks, global consumption has been rising rapidly for more than 50 years.

Read more Medical News

› Verified 7 days ago